Literature DB >> 9855424

Mucosal responses to parenteral and mucosal vaccines.

D Kaul1, P L Ogra.   

Abstract

Most human pathogens are acquired through mucosal portals of entry, and replicate in the mucosal tissues. Subsequently, the infecting agent may invade the blood stream and produce disease at distant systemic sites. However, a large number of pathogenic organisms are limited to development of disease only at the site of initial mucosal replication. Studies carried out with naturally acquired infections and mucosally delivered vaccines have provided strong evidence for the existence of a common mucosal immune system in the organized lymphoid follicles in respiratory and intestinal epithelium, and in the mucosa of genital tract, mammary glands, conjunctiva, upper airways, and the middle ear cavity. Mucosal application of live attenuated oral poliovaccine (OPV), rubella virus vaccine (RA 27/3), adenoviruses, influenza A virus, rotavirus, salmonella, and cholera vaccines have demonstrated consistent development of secretory IgA, serum antibody, and cellular immune responses. Mucosal immunization appears to result in preferential expression of several integrins and cell adhesion molecules associated with homing of lymphocytes to mucosal sites of immunization. Induction of mucosal immune responses often result in specific protection against reinfection challenge and against illness. Replicating agents introduced via the parenteral route also result in the development of mucosal responses and protection against systemic illness. Parenteral immunization with non-replicating agents often fails to induce specific mucosal responses. Such immunization, however, is quite effective in mounting high levels of serum antibody with development of protection against systemic illness. Parenteral vaccines, such as enhanced potency inactivated polio vaccine (eIPV), Haemophilus influenzae type B (HIB), hepatitis B virus (HBV), and other non-mucosal vaccines, have been highly effective in preventing systemic disease during subsequent exposure to natural infection. Recent evidence has shown that parenteral immunization can also be quite effective in inducing varying degrees of functional mucosal antibody responses as detected by ELISA and less frequently by neutralization. Systemic illnesses such as poliomyelitis and Haemophilus influenzae meningitis and community circulation of these agents has been eliminated or significantly limited in many parts of the world with the exclusive use of inactivated vaccines. Based on these observations, it is suggested that development of serum immunological responses are effective in the prevention of systemic disease regardless of the types of vaccines or route of their administration. However, induction of pathogen-specific antibody or cellular immunity at the mucosal sites is best elicited by mucosal application of the antigen.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9855424

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  14 in total

Review 1.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells.

Authors:  Igor M Belyakov; Scott A Hammond; Jeffrey D Ahlers; Gregory M Glenn; Jay A Berzofsky
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

3.  Mucosal delivery of bacterial antigens and CpG oligonucleotides formulated in biphasic lipid vesicles in pigs.

Authors:  Valeria Alcon; Maria Baca-Estrada; Marco Vega-Lopez; Philip Willson; Lorne A Babiuk; Praveen Kumar; Rolf Hecker; Marianna Foldvari
Journal:  AAPS J       Date:  2005-10-14       Impact factor: 4.009

4.  Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization.

Authors:  D Chen; S B Periwal; K Larrivee; C Zuleger; C A Erickson; R L Endres; L G Payne
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

5.  Intimin-specific immune responses prevent bacterial colonization by the attaching-effacing pathogen Citrobacter rodentium.

Authors:  M Ghaem-Maghami; C P Simmons; S Daniell; M Pizza; D Lewis; G Frankel; G Dougan
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

6.  Vaccination strategies to enhance local immunity and protection against Mycobacteriun tuberculosis.

Authors:  Peter Klucar; Peter F Barnes; Ying Kong; Susan T Howard; Xiuhua Pang; Fang-Fang Huang; Amy R Tvinnereim; Buka Samten; Homayoun Shams
Journal:  Vaccine       Date:  2009-03-13       Impact factor: 3.641

7.  Materials that harness and modulate the immune system.

Authors:  Jamal S Lewis; Krishnendu Roy; Benjamin G Keselowsky
Journal:  MRS Bull       Date:  2014-01-01       Impact factor: 6.578

8.  Possible correlates of long-term protection against Helicobacter pylori following systemic or combinations of mucosal and systemic immunizations.

Authors:  Jennifer M Taylor; Melanie E Ziman; Julie Fong; Jay V Solnick; Michael Vajdy
Journal:  Infect Immun       Date:  2007-05-14       Impact factor: 3.441

Review 9.  Innate endogenous adjuvants prime to desirable immune responses via mucosal routes.

Authors:  Xiaoguang Wang; Delong Meng
Journal:  Protein Cell       Date:  2014-12-13       Impact factor: 14.870

10.  Decreased IgA+ B cells population and IgA, IgG, IgM contents of the cecal tonsil induced by dietary high fluorine in broilers.

Authors:  Juan Liu; Hengmin Cui; Xi Peng; Jing Fang; Zhicai Zuo; Junliang Deng; Hesong Wang; Bangyuan Wu; Yuanxin Deng; Kangping Wang
Journal:  Int J Environ Res Public Health       Date:  2013-05-02       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.